GlassScriptPhysician profile
Diana Wagner
NPI 1790893022
$3,898.72
in general payments reported to CMS, 2019-2025
31 companies · $531 in 2025
The $531 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $321 · 2021: $522 · 2022: $411 · 2023: $628 · 2024: $775 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922 · Education: $12.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.77 |
| Education | $12.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,494.80 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $642.76 | 2019-2025 | Ozempic, Wegovy |
| Dexcom, INC. | $327.55 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $195.42 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $165.18 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $143.99 | 2019-2025 | Omnipod |
| Medtronic, INC. | $110.54 | 2021-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $78.80 | 2019-2021 | |
| Medtronic Minimed, INC. | $66.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.30 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $53.55 | 2024-2025 | Baqsimi |
| Amgen INC. | $49.35 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $46.97 | 2019-2023 | |
| Ultragenyx Pharmaceutical INC. | $46.17 | 2019 | |
| Antares Pharma, INC. | $43.14 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.66 | 2019 | |
| Ibsa Pharma INC. | $34.21 | 2019 | |
| Ascensia Diabetes Care US INC. | $30.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.05 | 2023 | |
| Janssen Pharmaceuticals, INC | $27.18 | 2019 | |
| Beta Bionics, INC. | $25.68 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Endo Pharmaceuticals INC. | $22.71 | 2020-2021 | |
| Sequel Med Tech, LLC | $22.59 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $20.72 | 2020 | |
| Radius Health, INC. | $20.07 | 2019 | |
| Cequr Corporation | $20.00 | 2023 | Cequr Simplicity |
| Gilead Sciences, INC. | $19.82 | 2019 | |
| Corcept Therapeutics | $16.75 | 2019 | |
| Companion Medical, INC. | $15.54 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $14.18 | 2019 | |
| Strongbridge US INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.